Table 4 Comparison electronic brachytherapy (EBT) and ¹⁹²Iridium brachytherapy (IBT)

Number of Patients Enrolled

65

75

Number of Patients Treated

44 (67.7%)

43 (57.3%)

Age: mean (range)

64 years (45-84)

69 years (50-90)

Menopausal Status: n (%)

   Pre-Menopausal

1 (2.3%)

0

   Peri-Menopausal

2 (4.6%)

2 (5%)

   Post-Menopausal

41 (93.2%)

41 (95%)

Tumor Size: mean (range)

1.2 cm (0.2-2.8 cm)

1.0 cm

AJCC Class: n (%)

   Tis

12 (27.3%)

0

   T1a

1 (2.3%)

9 (21%)

   T1b

8 (18.2%)

16 (37%)

   T1c

21 (47.7%)

18 (42%)

   T2

2 (4.6%)

0

Histopathologic Grade

   G1 Well Differentiated

12 (27.3%)

17 (40%)

   G2 Moderately Differentiated

18 (40.9%)

16 (37%)

   G3 Poorly Differentiated

10 (22.7%)

6 (14%)

   Grade Not Available

4 (9.1%)

4 (9%)

Minimum Distance from Balloon to Skin Surface

6 mm

5 mm

Breast Cup Size

   A

0

1 (2%)

   B

12 (27.3%)

9 (21%)

   C

16 (36.4%)

15 (35%)

   D+

11 (25.0%)

11 (26%)

   Not reported

5 (11.4%)

7 (16%)

Cosmesis

EBT

IBT

   Good - Excellent cosmesis at 1 month

35/44 (80%)

38/43 (88%)

   Good - Excellent cosmesis at 1 year

24/32 (75%)

--

   Good - Excellent cosmesis at 5 years

--

35/43 (81%)

Adverse Events in > 2 patients

EBT ^a

IBT ^b

Blistering

3 (6.8%)

2 (3.7%)

Bruising / hematoma

1 (2.3%)

3 (5.6%)

Catheter Site Drainage

0

28 (51.9%)

Desquamation, Dry

2 (4.5%)

7 (13.0%)

Desquamation, Moist

3 (6.8%)

3 (5.6%)

Dry Skin (Breast)

2 (4.5%)

6 (11.1%)

Ecchymosis

1 (2.3%)

17 (31.5%)

Edema (breast)

0

8 (14.8%)

Erythema, redness/rash

27 (61.4%)

31 (57.4%)

Fibrosis

2 (4.5%)

3 (5.6%)

Hyperpigmentation / Hypopigmentation

9 (20.5%)

5 (9.3%)

Induration

3 (6.8%)

1 (1.9%)

Infection

2 (4.5%)

2 (3.7%)

Itching / Pruritis

4 (9.1%)

5 (9.3%)

Pain, tenderness, discomfort

13 (29.5%)

23 (42.6%)

Rash

0

4 (7.4%)

Seroma

2 (4.5%)

6 (11.1%)

Skin Irritation

0

3 (5.6%)